Source:http://linkedlifedata.com/resource/pubmed/id/17944487
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
45
|
pubmed:dateCreated |
2007-11-6
|
pubmed:abstractText |
Metallo-beta-lactamases (MBLs) are considered an emerging family of Zn2+-dependent enzymes that significantly contribute to the resistance of many nosocomial pathogens against beta-lactam antimicrobials. Since these plasmid-encoded enzymes constitute specific molecular targets for beta-lactams, their exact mode of action is greatly important in deploying efficient anti-infective treatments and for the control of severe multi-resistant nosocomial infections, which becomes a global problem. A novel hybrid VIM-1/VIM-2-type beta-lactamase (named VIM-12) has recently been identified in a clinical isolate of Klebsiella pneumoniae in Greece. The sequence of this enzyme is highly similar with that of VIM-1 at its N-terminal region and with that of VIM-2 at its C-terminal region, raising the question of whether this sequence similarity reflects also a similar functional role. Moreover, the possible contribution of this novel beta-lactamase to the overall antibiotic resistance of this specific clinical isolate was investigated. The gene encoding VIM-12 was cloned and expressed, and the recombinant enzyme was used for detailed kinetic analysis, using a variety of beta-lactam antibiotics. VIM-12 was found to exhibit narrow substrate specificity, compared to other known beta-lactamases, limited mainly to penicillin and to a much lesser extent to imipenen. Interestingly, meropenem was found to act as a noncompetitive inhibitor of the enzyme, although the active site of VIM-12 exhibited complete conservation of residues among VIM enzymes. We conclude that VIM-12 represents a novel and unique member of the family of known metallo-beta-lactamases, exhibiting atypical substrate specificity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0006-2960
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
13
|
pubmed:volume |
46
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
13170-8
|
pubmed:meshHeading |
pubmed-meshheading:17944487-Aged,
pubmed-meshheading:17944487-Amino Acid Sequence,
pubmed-meshheading:17944487-Cloning, Molecular,
pubmed-meshheading:17944487-Escherichia coli,
pubmed-meshheading:17944487-Humans,
pubmed-meshheading:17944487-Kinetics,
pubmed-meshheading:17944487-Klebsiella Infections,
pubmed-meshheading:17944487-Klebsiella pneumoniae,
pubmed-meshheading:17944487-Molecular Sequence Data,
pubmed-meshheading:17944487-Sequence Alignment,
pubmed-meshheading:17944487-Substrate Specificity,
pubmed-meshheading:17944487-beta-Lactamases
|
pubmed:year |
2007
|
pubmed:articleTitle |
Molecular cloning and biochemical characterization of VIM-12, a novel hybrid VIM-1/VIM-2 metallo-beta-lactamase from a Klebsiella pneumoniae clinical isolate, reveal atypical substrate specificity.
|
pubmed:affiliation |
Department of Biochemistry and Biotechnology, University of Thessaly, 26 Ploutonos st., 41221 Larissa, Greece.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|